Efficacy News and Research

RSS

West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

West Pharmaceutical Services, Inc., a global leader in innovative packaging components and drug delivery systems, hosted a groundbreaking ceremony in Waterford, Ireland today to mark the start of construction for the company's new pharmaceutical component manufacturing facility. Attended by Cllr James Tobin, Mayor of Waterford City and County; Cllr Lola O'Sullivan, Mayor of Waterford Metropolitan District; and other local officials, the event celebrated West's continued investment in Ireland and commitment to the local Waterford community.

16 Jun 2015

Juniper announces enrollment of first patient in COL-1077 Phase II trial to reduce pain during endometrial biopsy

Juniper Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of therapeutics for women's health, announced today the first patient has been enrolled in a Phase II clinical trial of COL-1077, a 10% lidocaine bioadhesive gel that is intended as an acute-use anesthetic during minimally invasive gynecologic procedures.

15 Jun 2015

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

BIAL is presenting 11 research posters at the 19th International Congress of Parkinson's Disease and Movement Disorders (June 14–15, San Diego, CA). These evaluate the safety and efficacy of opicapone (BIA 9-1067), a novel once-daily catechol-O-methyltransferase (COMT) inhibitor for use as adjunctive therapy in levodopa-treated Parkinson’s disease patients with end of dose motor fluctuations.

15 Jun 2015

Vitamin D supplementation may treat Crohn’s disease

New research published in this month’s edition of United European Gastroenterology Journal suggests that supplementation with vitamin D may impact on the intestinal barrier dysfunction associated with Crohn’s disease, and could have a role in the treatment of the condition.

15 Jun 2015

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

Living Cell Technologies Limited today announced results from a Phase I/IIa clinical study of NTCELL, an experimental regenerative cell therapy being studied as a disease-modifying agent in Parkinson’s disease. The study, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL.

15 Jun 2015

Study shows bacteriophages remain active against P. aeruginosa infection after nebulization

bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. aeruginosa) after nebulization.

15 Jun 2015

ABC TV's science program impacts use of statins among Australians

More than 60,000 Australians are estimated to have reduced or discontinued their use of prescribed cholesterol-lowering statin medications following the airing of a two-part series critical of statins by ABC TV's science program, Catalyst, a University of Sydney study reveals in the latest Medical Journal of Australia.

15 Jun 2015

New evidence-based protocol to treat severe pain in emergency department patients

Simply asking the question, "Do you want more pain medication?" resulted in satisfactory pain control in 99 percent of emergency department patients participating in a study.

15 Jun 2015

People with rheumatoid arthritis less likely to benefit from hepatitis B vaccine

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that people with rheumatoid arthritis (RA) are less likely to be protected by hepatitis B vaccination than the general population.

14 Jun 2015

UIC study shows that brain cell density remains constant in normal aging

New, ultra-high-field magnetic resonance images (MRI) of the brain by researchers at the University of Illinois at Chicago provide the most detailed images to date to show that while the brain shrinks with age, brain cell density remains constant.

14 Jun 2015

Vitamin D supplementation may affect intestinal barrier dysfunction associated with Crohn's disease

New research published in this month's edition of United European Gastroenterology journal suggests that supplementation with vitamin D may impact on the intestinal barrier dysfunction associated with Crohn's disease, and could have a role in the treatment of the condition.

13 Jun 2015

Triciribine drug may reverse progression of pulmonary fibrosis and pulmonary hypertension

Researchers at the University of Georgia have discovered that the drug triciribine may reverse or halt the progression of pulmonary fibrosis and pulmonary hypertension, two respiratory diseases that are almost invariably fatal.

13 Jun 2015

Promising results for multi-source DBS in Parkinson’s disease

Deep-brain stimulation targeting the subthalamic nucleus with a multiple-source constant-current device effectively suppresses motor symptoms in patients with advanced Parkinson’s disease, report researchers.

12 Jun 2015

New therapy for osteoporosis may be in the pipeline

Researchers from The Scripps Research Institute (TSRI), Florida, have reported a novel therapeutic approach that could promote the formation of new bone cells in people suffering from bone loss.

12 Jun 2015

New cholesterol-lowering drugs have potential to prevent heart attack, stroke

On the brink of FDA approval is a new class of cholesterol-lowering drugs that have the potential to change the landscape in the prevention of heart attack and stroke.

12 Jun 2015

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Tioga Pharmaceuticals, a clinical stage biotechnology company, today announced the initiation of a Phase 2 clinical study of asimadoline, a novel, well-studied kappa-opioid receptor specific agonist, for the treatment of pruritus or itching. The double-blind, placebo-controlled clinical study is designed to evaluate the safety, tolerability, and clinical efficacy of asimadoline in patients with pruritus due to atopic dermatitis and is being conducted at 20 clinical study centers in the United States.

11 Jun 2015

Johns Hopkins researcher to help address solutions to antibiotic-resistant bacteria at White House

Johns Hopkins infectious disease researcher Sara Cosgrove, M.D., M.S., has been tapped by the White House to help address solutions to the ever-growing problem of antibiotic-resistant bacteria.

11 Jun 2015

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

Isis Pharmaceuticals, Inc. today provided an update on its ongoing open-label Phase 2 clinical study of ISIS-SMN Rx in infants with Type I spinal muscular atrophy (SMA).

11 Jun 2015

ESCMID introduces two new study groups to create networks for forensic and veterinary microbiology

The European Society of Clinical Microbiology and Infectious Diseases launched two new study groups; the Forensic and Postmortem Microbiology Study Group and the Veterinary Microbiology Study Group.

11 Jun 2015

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

This week, Lancet Oncology reports results of a 1,093-person phase III clinical trial of the drug necitumumab (IMC-11F8) combined with chemotherapies gemcitabine and cisplatin against stage IV squamous non-small cell lung cancer. With addition of necitumumab, median overall survival was 11.5 months compared with median survival of 9.9 months with the two chemotherapies alone.

11 Jun 2015

Efficacy News and Research

West Pharmaceutical Services hosts groundbreaking ceremony for new manufacturing facility in Ireland

Juniper announces enrollment of first patient in COL-1077 Phase II trial to reduce pain during endometrial biopsy

Clinical studies confirm safety, efficacy of opicapone in Parkinson’s disease patients

Vitamin D supplementation may treat Crohn’s disease

NTCELL Phase I/IIa clinical study meets primary endpoint in patients with Parkinson’s disease

Study shows bacteriophages remain active against P. aeruginosa infection after nebulization

ABC TV's science program impacts use of statins among Australians

New evidence-based protocol to treat severe pain in emergency department patients

People with rheumatoid arthritis less likely to benefit from hepatitis B vaccine

UIC study shows that brain cell density remains constant in normal aging

Vitamin D supplementation may affect intestinal barrier dysfunction associated with Crohn's disease

Triciribine drug may reverse progression of pulmonary fibrosis and pulmonary hypertension

Promising results for multi-source DBS in Parkinson’s disease

New therapy for osteoporosis may be in the pipeline

New cholesterol-lowering drugs have potential to prevent heart attack, stroke

Tioga Pharmaceuticals announces commencement of asimadoline Phase 2 study for treatment of pruritus

Johns Hopkins researcher to help address solutions to antibiotic-resistant bacteria at White House

Isis Pharmaceuticals provides update on ISIS-SMN Rx Phase 2 clinical study in infants with Type I SMA

ESCMID introduces two new study groups to create networks for forensic and veterinary microbiology

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News